Bausch + Lomb has announced it submitted a new drug application to FDA seeking approval for a once-daily topical nonsteroidal anti-inflammatory compound for the treatment of ocular inflammation and pain following cataract surgery, according to a news release.
The compound, named PROLENSA, was developed by recently acquired ISTA Pharmaceuticals.
"The PROLENSA filing is an important step towards bringing safe, effective and meaningful medical advances to medical professionals and their patients," said Marvin Garrett, vice president of U.S. regulatory affairs, quality assurance and compliance for Bausch + Lomb, in the release. "It's also a timely example of the progress we continue to make on critical D&R programs as we work to bring together the best of ISTA Pharmaceuticals and Bausch + Lomb."
Related Articles on FDA Clearances:
Medtronic Receives Expanded FDA Clearance for Pillar Palatal Implant System
St. Jude Receives FDA Clearance for Ultrasound Catheter
Kimberly-Clark Health Care Receives FDA Clearance for Sterilization Wrap Portfolio